The deal size was increased to $85M in common stock from $75M in common stock and the range was $3.75-$4.07. Jefferies, UBS, Citi and Barclays acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07
- SAB Biotherapeutics announces common stock offering, no amount given
- SAB Biotherapeutics price target raised to $14 from $12 at Chardan
- SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
- SAB Biotherapeutics announces additional Phase 1 data for SAB-142